Edition:
United Kingdom

T2 Biosystems Inc (TTOO.OQ)

TTOO.OQ on NASDAQ Stock Exchange Global Market

6.49USD
16 Aug 2018
Change (% chg)

$-0.07 (-1.07%)
Prev Close
$6.56
Open
$6.61
Day's High
$6.66
Day's Low
$6.39
Volume
82,891
Avg. Vol
197,823
52-wk High
$9.98
52-wk Low
$3.64

Chart for

About

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including... (more)

Overall

Beta: --
Market Cap(Mil.): $157.07
Shares Outstanding(Mil.): 35.14
Dividend: --
Yield (%): --

Financials

  TTOO.OQ Industry Sector
P/E (TTM): -- 32.29 32.76
EPS (TTM): -1.97 -- --
ROI: -113.02 13.92 14.61
ROE: -328.67 16.77 16.33

BRIEF-T2 Biosystems Reports Q1 Loss Per Share Of $0.36

* T2 BIOSYSTEMS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 May 2018

BRIEF-T2 Biosystems Files For Non Timely 10-K

* T2 BIOSYSTEMS INC FILES FOR NON TIMELY 10-K - SEC FILING‍​ Source text - http://bit.ly/2ppkjtC Further company coverage:

19 Mar 2018

BRIEF-T2 Biosystems Q4 Revenue Rose 55 Percent To $1.7 Million

* T2 BIOSYSTEMS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

06 Mar 2018

BRIEF-T2 Biosystems Awarded Up To $2 Million By Carb-X To Support Development Of New Tests On The T2Dx Instrument For Drug-Resistant Bacteria

* T2 BIOSYSTEMS AWARDED UP TO $2 MILLION BY CARB-X TO SUPPORT DEVELOPMENT OF NEW TESTS ON THE T2DX INSTRUMENT FOR DRUG-RESISTANT BACTERIA Source text for Eikon: Further company coverage:

06 Mar 2018

Earnings vs. Estimates